ASX rebounds; TikTok eyes Musk amid US ban
The ASX rebounded, with mining and energy stocks up. Meanwhile Star also bounced, thanks to a Macau backer, and TikTok may sell US arm to Elon Musk.
Stockhead
FIRB approval for Chinese potash investment
A potash company backed by Owen Hegarty’s EMR Capital received a boost as FIRB approved an investment from China Inc.
Road to 2025: Hot Chili
Stockhead recaps the successes of 2024 for Hot Chili and the big milestones it has planned for the months ahead.
ASX lifts as Macau investor backs Star
The ASX has bounced back a bit with energy and mining stocks rallying, while a mystery Macau investor scoops up Star Entertainment.
More Stories
New Age tastes Hemi-style gold at Wagyu
New Age Exploration’s Phase 2 drilling at its Wagyu gold project in WA has expanded locations of Hemi-style sulphide-rich intermediate intrusive rocks
Arizona clears three brine pads for take-off
Pad #3 has been completed at Arizona Lithium’s Prairie project, with drilling to start in the coming weeks as it eyes a 6000tpa LCE production target.
ASX Small Caps Lunch Wrap
Banks and Resources have pushed the ASX 200 to another record high on Tuesday.
PharmAust rebrands as Neurizon Therapeutics
Clinical stage biotech targeting human neurodegenerative diseases PharmAust has rebranded to Neurizon Therapeutics.
Top 10 at 11: Fresh from the ASX today
Good morning, and welcome to Stockhead’s Top 10 at 11, a short, sharp update to help frame the trading day.
Antipa prime for gold action in WA
Euroz’ Michael Scantlebury says Newmont’s exit at Telfer will lead to more Paterson Province M&A, with Antipa in the box seat.
How to supercharge stock picks with AI
These AI-powered tools enable investors to trade smart and fast.
A reinvention in the quest for MND treatment
True to its history of reinvention and repurposing, PharmAust is set to be renamed Neurizon Therapeutics as it continues its MND drug development quest.
Bitcoin jumps 5% as Nvidia chases records
Bitcoin jumps more than 5% after China’s lacklustre stimulus, while Nvidia climbs 2.5% as it nears record highs.
Chimeric seeks at least $5m in capital raising
Cancer cell therapy house Chimeric Therapeutics is going to the well for a much-needed capital raising to fund its clinical programs. Read more in our health wrap.
Original URL: https://www.ntnews.com.au/business/stockhead/page/195